Diabetic Neuropathy: Symptoms and Prevention

Diabetic neuropathy is the most common long-term complication of diabetes, affecting approximately 50% of adults with Type 2 diabetes of long duration and eventually developing in some form in most adults with Type 1 diabetes. Despite how common it is, diabetic neuropathy remains poorly understood by many adults with diabetes — they may experience the symptoms (numbness, tingling, pain in the feet) without knowing these sensations represent measurable nerve damage with specific clinical consequences, prevention strategies, and management options. Understanding diabetic neuropathy — what it is, how it develops, what the different types cause, and what can be done to slow its progression — is essential for any adult with diabetes who wants to protect their quality of life and reduce the risk of the most serious neuropathy-related outcome: foot ulcers and amputation. Most cases of amputation in people with diabetes are preceded by a foot ulcer, most foot ulcers develop in people who have lost protective sensation from diabetic neuropathy, and most cases of neuropathy are substantially accelerated by poorly controlled blood glucose over years — which means that the individual daily decisions about blood glucose management have a direct long-term impact on whether neuropathy develops and how fast it progresses.

Types of Diabetic Neuropathy and Their Symptoms

Diabetic neuropathy is not a single condition — it encompasses several distinct nerve damage patterns that affect different nerve types and produce different symptoms:

• Distal symmetric peripheral neuropathy (DSPN) — the most common form: DSPN affects the longest nerves first (those supplying the feet), causing a characteristic stocking-and-glove distribution of sensory symptoms that begins in the toes and feet and progresses proximally up the legs over years. The sensory symptoms are highly variable between individuals: some experience predominantly negative symptoms (numbness, loss of vibration sense, loss of position sense — proprioception), while others experience predominantly positive symptoms (tingling, burning pain, electric shock sensations, allodynia — pain from normally non-painful stimuli like bedsheets touching the feet). Approximately 10–20% of adults with diabetic neuropathy have significant neuropathic pain that substantially affects quality of life. In later stages, motor involvement causes intrinsic foot muscle weakness, leading to characteristic foot deformities (hammer toes, claw toes, Charcot foot) that create pressure points and further increase ulcer risk. Annual foot exams that screen for DSPN are in our foot exams for people with diabetes guide.
• Autonomic neuropathy: Autonomic neuropathy affects the nerves controlling involuntary organ functions. Cardiovascular autonomic neuropathy (CAN) causes resting tachycardia (heart rate above 100 bpm at rest), exercise intolerance, and orthostatic hypotension (blood pressure drop on standing — causing dizziness or fainting that increases fall risk). CAN is associated with significantly increased cardiovascular mortality and with silent myocardial ischemia — heart attacks without typical chest pain, which are more common in adults with diabetes due to autonomic blunting of the pain response. Gastrointestinal autonomic neuropathy causes gastroparesis — delayed gastric emptying that produces nausea, vomiting, early satiety, bloating, and unpredictable blood glucose excursions because food absorption timing is erratic. Genitourinary autonomic neuropathy causes bladder dysfunction (incomplete emptying, urinary retention, overflow incontinence) and sexual dysfunction (erectile dysfunction in men, reduced lubrication and arousal in women).
• Focal and multifocal neuropathies: These less common forms affect individual nerves or nerve roots, causing sudden-onset symptoms in a specific distribution: cranial neuropathy (sudden double vision from third cranial nerve palsy), thoracic radiculopathy (band-like chest or abdominal pain mimicking cardiac or surgical emergencies), lumbosacral radiculoplexus neuropathy (also called diabetic amyotrophy or Bruns-Garland syndrome — severe asymmetric thigh pain and muscle weakness, typically in older adults with Type 2 diabetes, that usually partially recovers over months to years). These are distinct from DSPN and generally have a different pathophysiology (ischemic infarction of nerve trunks rather than diffuse metabolic damage), which is why they tend to be more acute in onset and more likely to partially recover. The broader context of diabetic complications that includes neuropathy alongside retinopathy, nephropathy, and cardiovascular disease is in our diabetes complications: what adults should know guide.

How to Prevent Diabetic Neuropathy From Developing or Progressing

The prevention of diabetic neuropathy rests primarily on the same strategies that prevent other microvascular complications — with the clearest and most powerful evidence pointing to long-term blood glucose control as the dominant modifiable risk factor:

• Blood glucose control — the most powerful prevention strategy: The DCCT trial in Type 1 diabetes demonstrated that intensive blood glucose control (A1C target below 7.0%) reduced the development of clinical neuropathy by 60% compared to conventional control over 6.5 years. The EDIC follow-up extended this observation, showing that the neurological benefit of early intensive control persisted for 13–14 years after the trial — a metabolic memory effect demonstrating that glucose control in the early years of diabetes has lasting protective effects on nerve health that persist even if control later relaxes. In Type 2 diabetes, the UKPDS showed a significant reduction in neuropathy incidence with intensive glucose control, though the effect size was smaller than in Type 1 diabetes — likely because Type 2 diabetes is associated with additional risk factors (hypertension, dyslipidemia, obesity) that contribute to neuropathy beyond blood glucose alone. The A1C monitoring that tracks blood glucose control is in our A1C testing schedule guide.
• Blood pressure control: Hypertension contributes to neuropathy through multiple mechanisms including impaired microvascular blood supply to peripheral nerves (vasa nervorum — the tiny vessels that supply the nerve axons with oxygen and glucose). Adults with diabetes and hypertension have higher rates of peripheral neuropathy than adults with diabetes alone, and blood pressure control (target below 130/80 mmHg) provides some protective benefit. The blood pressure monitoring guide is our blood pressure monitoring in diabetes article.
• Physical activity: Regular aerobic exercise has been shown in multiple studies to improve peripheral nerve function in adults with diabetic neuropathy — improving nerve conduction velocity, reducing neuropathic pain scores, and improving quality of life. The mechanisms include improved microvascular perfusion of peripheral nerves, increased neurotrophic factor production (particularly nerve growth factor and brain-derived neurotrophic factor), improved mitochondrial function in nerve axons, and reduced systemic inflammation. Walking programs, cycling, and supervised resistance training all show benefit in neuropathy studies, with 150 minutes per week of moderate-intensity activity being the recommended minimum for cardiovascular and metabolic benefit.
• Smoking cessation: Smoking significantly accelerates peripheral neuropathy by impairing microvascular blood flow to peripheral nerves through nicotine-driven vasoconstriction and carbon monoxide-mediated reduction in oxygen delivery. Adults with diabetes who smoke have substantially higher rates of peripheral neuropathy and peripheral arterial disease than non-smoking adults with diabetes. Smoking cessation is one of the highest-impact actions for both neuropathy prevention and overall cardiovascular risk reduction. The foot care practices that protect neuropathic feet from ulcers and infection are in our diabetic foot problems: prevention and care guide. The annual foot exam that screens for neuropathy each year is in our foot exams for people with diabetes guide. The complete annual monitoring schedule is in our annual diabetes care checklist. The ADA’s diabetic neuropathy resources, the NIDDK’s nerve damage in diabetes information, and the CDC’s diabetic neuropathy overview provide authoritative clinical information on neuropathy screening, prevention, and management.

How Diabetic Neuropathy Is Diagnosed

Screening and diagnosis of diabetic neuropathy uses a combination of clinical history, symptom assessment, and bedside examination tests — with neurophysiology studies (nerve conduction studies) used for confirmation in uncertain cases or for clinical trial purposes:

• 10-gram monofilament test: The Semmes-Weinstein 10-gram monofilament is the most widely used and most clinically relevant bedside test for loss of protective sensation. The nylon filament is pressed perpendicularly against the skin surface at standardized sites on the plantar surface of the foot (typically the hallux, the ball of the foot beneath the first and fifth metatarsal heads, and the heel) with just enough force to bend the filament, then the patient (with eyes closed) indicates whether and where they feel the touch. A single site at which the touch cannot be felt indicates clinically significant loss of protective sensation — placing the patient at elevated risk of undetected foot injuries. The 10-gram monofilament test predicts foot ulcer risk more directly than any other bedside test and is recommended annually by the ADA as the minimum screening standard for peripheral neuropathy in adults with diabetes.
• 128-Hz tuning fork (vibration sense testing): Loss of vibration sense from large fiber neuropathy is typically the earliest detectable abnormality in diabetic peripheral neuropathy, preceding the loss of light touch and pressure sensation detected by the monofilament. The 128-Hz tuning fork is applied to the bony prominence at the base of the great toe bilaterally; the patient indicates when they no longer feel the vibration. Adults who lose vibration sense significantly earlier than the examiner (whose normal vibration sense serves as the comparison) have large fiber neuropathy. Vibration sense loss combined with intact monofilament sensation suggests early neuropathy that has not yet progressed to loss of protective sensation; monofilament loss represents advanced large fiber involvement.
• Ankle reflex testing: Loss of the Achilles tendon reflex (ankle jerk) is common in distal symmetric peripheral neuropathy and reflects involvement of the S1 nerve root arc mediated by the tibial nerve and large sensory fibers from the Achilles tendon. Absent ankle reflexes in both legs in a person with diabetes, without another neurological explanation, is consistent with peripheral neuropathy. The reflex is tested by tapping the Achilles tendon with a reflex hammer with the foot in neutral dorsiflexion.
• Temperature and pin-prick testing (small fiber neuropathy assessment): Small fiber neuropathy — affecting the thin unmyelinated C fibers and lightly myelinated A-delta fibers that carry pain and temperature sensation — can present with burning pain, allodynia, and autonomic symptoms without abnormalities on the standard large-fiber tests (monofilament, vibration, and nerve conduction studies). Bedside pin-prick testing (using a disposable safety pin) and warm/cold temperature discrimination testing assess small fiber function. Skin punch biopsy for intraepidermal nerve fiber density measurement and quantitative sensory testing provide more formal small fiber neuropathy assessment when clinical testing is inconclusive. The foot examination guide that covers neuropathy screening in the context of the full annual foot exam is our foot exams for people with diabetes article.

Managing Neuropathic Pain in Diabetes

For adults with diabetic neuropathy who experience significant neuropathic pain — burning, tingling, electric shock sensations, or allodynia — several evidence-based pharmacological treatments are available. Pain management does not treat the underlying nerve damage or slow neuropathy progression, but it significantly improves quality of life in adults with painful neuropathy:

• First-line treatments — duloxetine, pregabalin, gabapentin: Duloxetine (a serotonin-norepinephrine reuptake inhibitor, SNRI) is FDA-approved for diabetic peripheral neuropathic pain and is often recommended as first-line therapy — it provides meaningful pain reduction in approximately 50–60% of adults with painful diabetic neuropathy, with the additional benefit of treating comorbid depression which is common in this population. Pregabalin and gabapentin (calcium channel alpha-2-delta ligands) reduce neuronal excitability in sensitized nociceptive neurons and reduce neuropathic pain, with FDA approval for painful diabetic peripheral neuropathy for pregabalin. Both are sedating at higher doses and require dose titration; gabapentin requires more frequent dosing than pregabalin due to its shorter half-life and non-linear pharmacokinetics.
• Tricyclic antidepressants (amitriptyline, nortriptyline) — effective but with more side effects: Low-dose tricyclic antidepressants have substantial evidence for neuropathic pain reduction in multiple pain conditions including diabetic neuropathy, but their side effects (anticholinergic effects — dry mouth, constipation, urinary retention, cognitive impairment, and cardiac arrhythmia risk at higher doses) limit their use, particularly in older adults. Nortriptyline is generally better tolerated than amitriptyline due to fewer anticholinergic side effects.
• Topical treatments for localized pain: Topical capsaicin (0.075% cream or 8% patch) depletes substance P from local sensory nerve endings, reducing pain signal transmission. The 8% capsaicin patch (Qutenza) requires application by a healthcare provider and can produce 12 weeks of meaningful pain relief from a single application. Topical lidocaine (cream or patch) provides local anesthetic pain relief without systemic side effects, making it useful for localized allodynia. The complete diabetes complication context that places neuropathy alongside other long-term complications is in our diabetes complications: what adults should know guide. The foot protection practices essential for adults with neuropathic feet are in our diabetic foot problems: prevention and care guide. The annual diabetes care checklist that coordinates all monitoring including neuropathy assessment is our annual diabetes care checklist. The ADA’s neuropathy resources, the NIDDK’s nerve damage information, and the CDC’s diabetic neuropathy overview provide authoritative clinical information on diabetic neuropathy diagnosis, prevention, and pain management.

Living With Diabetic Neuropathy: Protecting Your Feet Every Day

For adults who already have established diabetic neuropathy with loss of protective sensation, daily foot protection becomes one of the most important self-management practices — because the absence of pain means that injuries which would normally prompt immediate attention in people with normal sensation instead go unnoticed until they have progressed to infected ulcers:

• Inspect feet daily without exception: Adults with diabetic peripheral neuropathy and loss of protective sensation should inspect both feet — including the soles and between the toes — every single day for cuts, blisters, calluses, swelling, redness, or any change in skin integrity. This inspection should be done in good lighting; a hand mirror or smartphone camera can help visualize the sole for adults with limited flexibility. Any break in skin integrity in a person with loss of protective sensation is a potential entry point for infection that requires prompt attention — same-day contact with a healthcare provider if there is redness, warmth, swelling, discharge, or any sign of infection. The detailed foot care guide is our diabetic foot problems: prevention and care article.
• Never walk barefoot — indoors or outdoors: Adults with peripheral neuropathy should never walk barefoot, even inside the home. Foreign objects (glass shards, staples, sharp debris) on the floor that would be immediately felt and avoided by someone with normal sensation are completely unfelt by someone with loss of protective sensation. Purpose-made diabetic footwear — well-fitted shoes with wide toe boxes, cushioned insoles, and no internal seams that create pressure points — are important for daily wear. Therapeutic shoes and custom orthotics may be covered by Medicare and other insurance for adults with documented diabetic neuropathy.
• Wash feet daily with lukewarm water — test temperature with elbow or wrist: Adults with neuropathy who have lost temperature sensation should never use hot water to wash feet — they cannot feel burns. Water temperature should be tested with the elbow or wrist (which have normal sensation) before immersing the feet. Pat feet dry gently, paying particular attention to between the toes where moisture accumulation promotes fungal infection. Apply moisturizer to the tops and soles of the feet (but not between the toes) to prevent dry cracked skin that creates entry points for bacteria.
• Attend annual comprehensive foot exams: The ADA recommends annual comprehensive foot examinations for all adults with diabetes — assessing skin integrity, foot pulses, vibratory sensation, monofilament testing, ankle reflexes, and foot structure. Adults who have already lost protective sensation should be examined more frequently — every 3–6 months — and should have any callus or corn addressed by a podiatrist rather than self-treating with over-the-counter callus removers (which can cause chemical burns that the person with neuropathy cannot feel). The foot exam guide that explains what the annual assessment covers is our foot exams for people with diabetes guide. The complete annual monitoring schedule that includes foot exams alongside all other diabetes monitoring components is in our annual diabetes care checklist. The kidney monitoring that is part of complete neuropathy and complication assessment is in our kidney tests for diabetes monitoring guide. The A1C monitoring that tracks the primary driver of neuropathy progression is in our A1C testing schedule guide. The ADA’s neuropathy and foot care resources, the NIDDK’s nerve damage in diabetes guide, and the CDC’s diabetic neuropathy overview provide authoritative information on living with and preventing diabetic neuropathy.

Diabetic neuropathy is one of the most common and most consequential complications of diabetes — but it is also one of the most modifiable when identified early and when the underlying drivers (elevated blood glucose, elevated blood pressure, smoking) are addressed. Adults who know the symptoms of neuropathy, attend annual foot exams, protect their neuropathic feet with daily inspection and appropriate footwear, and work to keep their A1C within target are doing everything available to slow neuropathy progression and prevent the foot ulcers and amputations that represent its most serious outcomes. For adults who are already experiencing neuropathic pain, effective pharmacological treatments can substantially reduce the pain burden and improve daily quality of life — but accessing those treatments requires bringing the symptoms to the attention of the clinical team rather than tolerating them silently as an expected part of having diabetes. Neuropathic symptoms are not something to simply endure; they are a signal worth discussing at every diabetes appointment.

Sources: American Diabetes Association — Standards of Medical Care in Diabetes, neuropathy screening and management recommendations; NIDDK — nerve damage in diabetes overview; CDC — diabetic neuropathy information; DCCT/EDIC — intensive glucose control and neuropathy prevention in Type 1 diabetes (60% risk reduction with intensive control); UKPDS — neuropathy incidence reduction with intensive blood glucose control in Type 2 diabetes; diabetic peripheral neuropathy epidemiology (50% prevalence in long-duration Type 2 diabetes); distal symmetric peripheral neuropathy — sensory and motor symptom distribution, monofilament testing, vibration testing; cardiovascular autonomic neuropathy — resting tachycardia, orthostatic hypotension, silent myocardial ischemia; gastroparesis — mechanisms, symptoms, blood glucose unpredictability; physical activity and peripheral nerve function improvement evidence; smoking effects on peripheral nerve vasculature in diabetes; neuropathic pain management — duloxetine, pregabalin, gabapentin, tricyclic antidepressants; loss of protective sensation and foot ulcer — amputation pathway.